Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy.

Onco Targets Ther · 2019 · PMC6535081 · PMID 31190894

Europe PMC DOI

hedged sentence

0.0490

closest p · 1.0× alpha

0.0490

boldest claim

The sentences

showed a trendP =0.049actually significant

In addition, ER negativity also showed a trend of higher pCR rate at NAT (OR: 3.36, 95%CI: 1.00–11.25, P =0.049).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.